India, April 27 -- Erasca, Inc. (ERAS) will host a conference call and webcast today to discuss preliminary Phase 1 dose-escalation data for ERAS-0015, its investigational pan-RAS molecular glue being developed for patients with RAS-mutant solid tumors. The company said early findings suggest a potentially best-in-class profile, with encouraging safety, tolerability, and early signs of anti-tumor activity.
RAS-mutant cancers are among the most common and difficult-to-treat solid tumors. These mutations drive aggressive disease across multiple tumor types, and treatment options remain limited, especially for patients who develop resistance to mutant-selective inhibitors.
Early Phase 1 dose-escalation findings
ERAS-0015 is being evaluated ...